postoperative pain management
Conditions
Interventions
Bupivacaine liposome group:Before anesthesia began, the operator administered bupivacaine liposomes (266mg, 20ml, 4ml each intercostal) to the 2-6th rib for intercostal nerve block under B-ultrasound
Bupivacaine hydrochloride group:Prior to anesthesia, 0.25% bupivacaine hydrochloride (15ml, 37.5mg, 3ml each intercostal) was administered by the operator under B-ultrasound guidance for intercostal n
Sponsors
The 10th Affiliated Hospital of Southern Medical University (Dongguan People's Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) The subjects have a full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign the informed consent; 2) Patients undergoing thoracoscopic thoracic surgery with general anesthesia; 3) Age 18-65 years old, gender unlimited; 4)18 kg/m2=BMI=30 kg/m2; 5) American Society of Anesthesiologists (ASA) Grade II-III.
Exclusion criteria
Exclusion criteria: 1) People who are allergic to bupivacaine liposomes, bupivacaine hydrochloride, opioids and other ingredients or components that may be used in the study; 2) Patients with long-term use of narcotic analgesics, sedatives or non-steroidal anti-inflammatory drugs; 3) Patients with systemic hypotension despite the use of vasoactive drugs; 4) Bradycardia, heart rate < 55 beats/min; 5) High atrioventricular block without pacemaker; 6) Complicated with craniocerebral injury and intracranial hypertension; 7) Patients with severe heart, lung, liver and renal dysfunction; 8) Patients with a history of allergic disease, malignant hyperthermia in the past, and epilepsy in the past; 9) Subjects with a history of mental illness and cognitive dysfunction; 10) Fat metabolism disorders; 11) Predictable difficulty intubation; 12) Patients with myasthenia gravis; 13) Subjects with sensory disorders such as hyperalgesia; 14) History of alcoholism; 15) Other circumstances in which the investigator determines that the subject is not suitable for participation in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS pain scores at rest and exercise (cough) within 72 hours after surgery;; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative opioid consumption within 72h after surgery;Postoperative pulmonary complication rate;Number of times the analgesic pump was pressed within 72h after surgery;length of stay;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactXie Haihui
The 10th Affiliated Hospital of Southern Medical University (Dongguan People's Hospital)
Outcome results
None listed